KF
KIN

Krilogy Financial’s Kindred Biosciences, Inc. KIN Stock Holding History

Krilogy Financial’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-9,090
Closed -$127K – 757
2018
Q3 		$127K Buy
+9,090
New +$123K 0.03% 185

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Krilogy Financial's KIN Position: Q4 2018 in Review

Krilogy Financial sold out of Kindred Biosciences, Inc. (KIN) in Q4 2018, closing a stake of 9,090 shares — an estimated $127K sold.

Krilogy Financial first reported a position in KIN in Q3 2018 and held it in 1 quarter. The position peaked at $127K in Q3 2018. 72 funds tracked by Wall St. Rank hold KIN as of Q4 2018.

  • Krilogy Financial reported no remaining Kindred Biosciences, Inc. position as of Q4 2018 after selling out during the quarter.
  • Krilogy Financial sold 9,090 Kindred Biosciences, Inc. shares in Q4 2018, an estimated $127K.
  • Krilogy Financial first reported a position in Kindred Biosciences, Inc. in Q3 2018 and held it in 1 quarter.
  • Krilogy Financial's Kindred Biosciences, Inc. position peaked at $127K in Q3 2018.
  • 72 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q4 2018.

Based on Krilogy Financial's 13F filing for Q4 2018, filed 14 Feb 2019.